Literature DB >> 17470167

How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life.

Yoshikazu Sato1, Hitoshi Tanda, Shuji Kato, Shigeki Onishi, Toshikazu Nitta, Mikio Koroku.   

Abstract

OBJECTIVES: To study the dropout rate for use of sildenafil after initial prescription and during successful treatment to clarify their risk factors.
METHODS: A total of 1036 patients with erectile dysfunction who were treated with sildenafil were analyzed. The dropout rate during successful treatment and its risk factors were assessed using the Kaplan-Meier method and Cox proportional hazards model, respectively.
RESULTS: Thirty-one percent (n = 322) of the patients dropped out after the initial prescription. The cumulative dropout rate during successful treatment at 3 years after starting usage was 48%. A lower International Index of Erectile Function (IIEF-5) score before treatment was a significant risk factor for dropout during a successful treatment course (P < 0.029 by the Cox proportional hazards model).
CONCLUSIONS: Approximately 30% and 50% of the patients dropped out of treatment after the first prescription and at 3-year follow-up, respectively. Adequate initial instruction and long-term follow-up are required even for patients with successful treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470167     DOI: 10.1111/j.1442-2042.2007.01608.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  8 in total

1.  Sexual medicine: Why stop a good thing? Discontinuing PDE5 inhibitors.

Authors:  Helen M Conaglen; John V Conaglen
Journal:  Nat Rev Urol       Date:  2012-08-14       Impact factor: 14.432

2.  Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.

Authors:  W-K Tsai; B-P Jiann
Journal:  Int J Impot Res       Date:  2014-01-23       Impact factor: 2.896

Review 3.  Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review.

Authors:  Paul Williams; Hayley McBain; Aliya Amirova; Stanton Newman; Kathleen Mulligan
Journal:  Int J Impot Res       Date:  2020-03-31       Impact factor: 2.896

4.  Validation of Portuguese version of Quality of Erection Questionnaire (QEQ) and comparison to International Index of Erectile Function (IIEF) and RAND 36-Item Health Survey.

Authors:  Ana Luiza Reis; Leonardo Oliveira Reis; Ricardo Destro Saade; Carlos Alberto Santos; Marcelo Lopes de Lima; Adriano Fregonesi
Journal:  Int Braz J Urol       Date:  2015 Jan-Feb       Impact factor: 1.541

Review 5.  Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil.

Authors:  Emmanuele A Jannini; Stéphane Droupy
Journal:  Sex Med       Date:  2018-12-03       Impact factor: 2.491

Review 6.  The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.

Authors:  A Zucchi; E Costantini; F I Scroppo; M Silvani; Z Kopa; E Illiano; M G Petrillo; L Cari; G Nocentini
Journal:  Andrology       Date:  2019-07-26       Impact factor: 3.842

7.  Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.

Authors:  Konstantinos Giannitsas; Angelis Konstantinopoulos; Christos Patsialas; Petros Perimenis
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

Review 8.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.